These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
119 related items for PubMed ID: 9699650
1. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y, Tanigawara Y, Lush RD, Headlee D, Figg WD, Arbuck SG, Senderowicz AM, Sausville EA, Akinaga S, Kuwabara T, Kobayashi S. Cancer Res; 1998 Aug 01; 58(15):3248-53. PubMed ID: 9699650 [Abstract] [Full Text] [Related]
6. Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine. Sparreboom A, Chen H, Acharya MR, Senderowicz AM, Messmann RA, Kuwabara T, Venzon DJ, Murgo AJ, Headlee D, Sausville EA, Figg WD. Clin Cancer Res; 2004 Oct 15; 10(20):6840-6. PubMed ID: 15501960 [Abstract] [Full Text] [Related]
7. Physiological modeling of altered pharmacokinetics of a novel anticancer drug, UCN-01 (7-hydroxystaurosporine), caused by slow dissociation of UCN-01 from human alpha1-acid glycoprotein. Fuse E, Hashimoto A, Sato N, Tanii H, Kuwabara T, Kobayashi S, Sugiyama Y. Pharm Res; 2000 May 15; 17(5):553-64. PubMed ID: 10888307 [Abstract] [Full Text] [Related]
8. Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models. Sausville EA, Lush RD, Headlee D, Smith AC, Figg WD, Arbuck SG, Senderowicz AM, Fuse E, Tanii H, Kuwabara T, Kobayashi S. Cancer Chemother Pharmacol; 1998 May 15; 42 Suppl():S54-9. PubMed ID: 9750030 [Abstract] [Full Text] [Related]
9. The effect of different dosing schedules of UCN-01 on its pharmacokinetics and cardiohaemodynamics in dogs. Kurata N, Imabeppu S, Nitoh M, Kobayashi H, Kuwabara T, Kobayashi S. J Pharm Pharmacol; 2000 Nov 15; 52(11):1327-35. PubMed ID: 11186240 [Abstract] [Full Text] [Related]
15. Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumor activity. Hill DL, Tillery KF, Rose LM, Posey CF. Cancer Chemother Pharmacol; 1994 Nov 15; 35(1):89-92. PubMed ID: 7987983 [Abstract] [Full Text] [Related]
17. Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850). Perez RP, Lewis LD, Beelen AP, Olszanski AJ, Johnston N, Rhodes CH, Beaulieu B, Ernstoff MS, Eastman A. Clin Cancer Res; 2006 Dec 01; 12(23):7079-85. PubMed ID: 17145831 [Abstract] [Full Text] [Related]
18. Tryptophan residues play an important role in the extraordinarily high affinity binding interaction of UCN-01 to human alpha-1-acid glycoprotein. Katsuki M, Chuang VT, Nishi K, Suenaga A, Otagiri M. Pharm Res; 2004 Sep 01; 21(9):1648-55. PubMed ID: 15497692 [Abstract] [Full Text] [Related]